Efavirenz: a decade of clinical experience in the treatment of HIV.

J Antimicrob Chemother · 2009 · PMC2760464 · PMID 19767318

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

74 Compared with patients switched to efavirenz, those switched to nevirapine were more likely to experience treatment failure (HR 0.63; 95% CI 0.54–0.74), while those switched to abacavir showed a trend for increased risk of failure (HR 0.84; 95% CI 0.68–1.04).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.